LTG-001 not checked

Latigo Biotherapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Main trialPhase 1
“This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants”In the company’s words, NCT06049095 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Sep 2026 A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants
Phase 2Completed 8 Aug 2025 This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars
Phase 2Completed 7 Jan 2026 An Efficacy and Safety Study of LTG-001 Following Abdominoplasty
Phase 1Completed 17 Nov 2025 A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LTG-001

Following is part of Solo: you see every change to LTG-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in